Ribociclib User Reviews & Ratings (Page 2)
Brand names: Kisqali
Ribociclib has an average rating of 8.3 out of 10 from a total of 28 reviews on Drugs.com. 80% of reviewers reported a positive experience, while 8% reported a negative experience.
Reviews for Ribociclib
- 123
- Taken for 1 to 6 months
- November 25, 2022
For Breast Cancer "2 cycles & tumour is spreading ....efficacy of drug not known"
- Samy
- Taken for less than 1 month
- December 4, 2019
For Breast Cancer, Metastatic "I have taken ribociclib for less than 10 days and develop a severe infection and very low white cells so I had to stay at hospital for 10 days to clear my infection"
Reviews may be edited to correct grammar/spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest are not published. This information is not intended to endorse any particular medication. While these reviews may be helpful, they are not a substitute for the expertise, knowledge, and judgement of healthcare professionals.
More about ribociclib
- Check interactions
- Compare alternatives
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- Drug class: CDK 4/6 inhibitors
- Breastfeeding
Kisqali (ribociclib) for Breast Cancer, Metastatic "With Breast Cancer, Metastasis I am feeling very much better, while using Kisqali. But do have body pains but that can be manageable. Now I can easily run my job and home affairs."